I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Infectious Disease Hepatitis B virus infection

Hepatitis B virus infection

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Mar 29 / Roche and Genentech
Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the Piranga phase 2, randomized, controlled, adaptive, open-label platform study
This presentation reports the primary and selected secondary and exploratory endpoint results from the Piranga (NCT04225715) phase 2 platform study. The combination of xalnesiran (RO7445482), a GalNAc-conjugated small interfering ribonucleic acid (siRNA) targeting HBsAg transcripts, with the checkpoint inhibitor PD-L1 LNA (RO7191863), a GalNAc-conjugated locked nucleic acid inhibiting the expression of the programmed death-ligand 1, either concurrently or sequentially, achieved limited efficacy on HBsAg loss and its durability. Xalnesiran with PD-L1 LNA was generally safe and well-tolerated.
Infectious Disease Hepatitis B virus infection APASL-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 29 / Roche and Genentech
Similarities and differences of xalnesiran-based combination regimens aimed to achieve functional cure in the Piranga phase 2 platform study
This exploratory post-hoc analysis reports on similarities and differences between the different xalnesiran-based combinations evaluated in the Piranga phase 2 platform trial, shedding light on findings that may explain the observed primary results. The combination of xalnesiran with peginterferon α achieved high rates of HBsAg loss through an increase in depth of HBsAg reduction, specifically in pts with low baseline HBsAg. Moreover, the absence of association between on-treatment ALT elevation and the HBsAg reduction or loss indicates that ALT flares may not be required to achieve HBsAg loss with xalnesiran-based combination regimen.
Infectious Disease Hepatitis B virus infection APASL-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 27 / Roche and Genentech
A novel mechanistic viral dynamics modeling (MVDM) framework to characterize the effect of combination therapies in chronic hepatitis B and evaluate the influence of individual characteristics in the Piranga phase 2 platform study
This poster present the MVDM framework, which is a novel tool capable of modeling the underlying biological mechanisms and predicting the time course of HBV biomarkers. Using it with the extensive data available in the Piranga trial, we showed that the effect of xalnesiran is influenced by the distribution of HBV genotype but the overall impact is minimal when xalnesiran is combined with a potent immunomodulator such as peginterferon α.
Infectious Disease Hepatitis B virus infection APASL-2025
Upcoming congresses
Access to Roche and Genentech’s latest medical information

Sign up or login to unlock the full suite of MEDICALLY features
May 7 - May 10, 2025 / Amsterdam, Netherlands
EASL 2025
Infectious Disease Oncology Hepatitis B virus infection
Subject:
European Association for the Study of the Liver - EASL Congress 2025
Venue:
Medical Booth Number:
Notify me

Sign up or login to unlock the full suite of MEDICALLY features
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.